Molecular mechanisms of resistance and toxicity associated with platinating agents

Cancer Treatment Reviews

Volumn 33, Issue 1, 2007, Pages 9-23

  Rabik, Cara A ^a   Dolan, M Eileen ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Cisplatin; DNA damage; Drug resistance

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; AMIFOSTINE; CARBAMAZEPINE; CARBOPLATIN; CISPLATIN; DIURETIC AGENT; ERYTHROPOIETIN; GABAPENTIN; GLUCONATE CALCIUM; GLUTATHIONE; HIGH MOBILITY GROUP PROTEIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LEVACECARNINE; MAGNESIUM SULFATE; METALLOTHIONEIN; METHIONINE; MULTIDRUG RESISTANCE PROTEIN 2; ORGANIC CATION TRANSPORTER; OXALIPLATIN; PACLITAXEL; PLATINUM COMPLEX; PROTEIN C FOS; REACTIVE OXYGEN METABOLITE; SATRAPLATIN; SODIUM THIOSULFATE; THIOREDOXIN; TIOPRONIN; TRANSPLATIN; UNINDEXED DRUG;

ADVANCED CANCER; ATAXIA; BONE MARROW SUPPRESSION; CANCER RELAPSE; CLINICAL TRIAL; COLORECTAL CANCER; CROSS LINKING; DNA ADDUCT; DNA DAMAGE; DNA REPAIR; DNA STRAND BREAKAGE; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SENSITIVITY; DRUG STRUCTURE; DRUG UPTAKE; ENDOMETRIUM CANCER; ENDOPLASMIC RETICULUM STRESS; EXCISION REPAIR; GYNECOLOGIC CANCER; HEAD AND NECK CANCER; HEAD AND NECK TUMOR; HOMOLOGOUS RECOMBINATION; HUMAN; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MELANOMA; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; NEPHROTOXICITY; NEUROPROTECTION; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; OTOTOXICITY; OVARY CANCER; OVARY TUMOR; PERIPHERAL NEUROPATHY; PROSTATE CANCER; REVIEW; SENSORY NEUROPATHY; THROMBOCYTOPENIA;

ANTINEOPLASTIC AGENTS; CARBOPLATIN; CISPLATIN; DNA DAMAGE; DNA, NEOPLASM; DRUG RESISTANCE, NEOPLASM; HUMANS; ORGANOPLATINUM COMPOUNDS; PLATINUM COMPOUNDS; SIGNAL TRANSDUCTION;

EID: 33846404174     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ctrv.2006.09.006     Document Type: Review

References (169)

1. Rosenberg B., et al. Platinum compounds: a new class of potent antitumour agents. Nature 222 191 (1969) 385-386
2. Kartalou M., and Essigmann J.M. Mechanisms of resistance to cisplatin. Mutat Res 478 1-2 (2001) 23-43
3. Wang D., and Lippard S.J. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 4 4 (2005) 307-320
4. Samimi G., et al. Novel mechanisms of platinum drug resistance identified in cells selected for resistance to JM118 the active metabolite of satraplatin. Cancer Chemother Pharmacol (2006)
5. Sternberg C.N., et al. Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer. Oncology 68 1 (2005) 2-9
6. Zorbas H., and Keppler B.K. Cisplatin damage: are DNA repair proteins saviors or traitors to the cell?. Chembiochem 6 7 (2005) 1157-1166
7. Woynarowski J.M., et al. Sequence- and region-specificity of oxaliplatin adducts in naked and cellular DNA. Mol Pharmacol 54 5 (1998) 770-777
8. Woynarowski J.M., et al. Oxaliplatin-induced damage of cellular DNA. Mol Pharmacol 58 5 (2000) 920-927
9. Faivre S., et al. DNA strand breaks and apoptosis induced by oxaliplatin in cancer cells. Biochem Pharmacol 66 2 (2003) 225-237
10. Fuertes M.A., Alonso C., and Perez J.M. Biochemical modulation of cisplatin mechanisms of action: enhancement of antitumor activity and circumvention of drug resistance. Chem Rev 103 3 (2003) 645-662
11. Di Francesco A.M., Ruggiero A., and Riccardi R. Cellular and molecular aspects of drugs of the future: oxaliplatin. Cell Mol Life Sci 59 11 (2002) 1914-1927
12. Misset J.L., et al. Oxaliplatin clinical activity: a review. Crit Rev Oncol Hematol 35 2 (2000) 75-93
13. Eastman A., and Barry M.A. Interaction of trans-diamminedichloroplatinum(II) with DNA: formation of monofunctional adducts and their reaction with glutathione. Biochemistry 26 12 (1987) 3303-3307
14. Vaisman A., et al. Effect of DNA polymerases and high mobility group protein 1 on the carrier ligand specificity for translesion synthesis past platinum-DNA adducts. Biochemistry 38 34 (1999) 11026-11039
15. Reeves R., and Adair J.E. Role of high mobility group (HMG) chromatin proteins in DNA repair. DNA Repair (Amst) 4 8 (2005) 926-938
16. Siddik Z.H. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22 47 (2003) 7265-7279
17. He Q., Liang C.H., and Lippard S.J. Steroid hormones induce HMG1 overexpression and sensitize breast cancer cells to cisplatin and carboplatin. Proc Natl Acad Sci USA 97 11 (2000) 5768-5772
18. Mandic A., et al. Cisplatin induces endoplasmic reticulum stress and nucleus-independent apoptotic signaling. J Biol Chem 278 11 (2003) 9100-9106
19. Breckenridge D.G., et al. Regulation of apoptosis by endoplasmic reticulum pathways. Oncogene 22 53 (2003) 8608-8618
20. Nakagawa T., and Yuan J. Cross-talk between two cysteine protease families. Activation of caspase-12 by calpain in apoptosis. J Cell Biol 150 4 (2000) 887-894
21. Nawrocki S.T., et al. Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis. Cancer Res 65 24 (2005) 11658-11666
22. Kashani-Sabet M., Wang W., and Scanlon K.J. Cyclosporin A suppresses cisplatin-induced c-fos gene expression in ovarian carcinoma cells. J Biol Chem 265 19 (1990) 11285-11288
23. Scanlon K.J., et al. Ribozyme-mediated cleavage of c-fos mRNA reduces gene expression of DNA synthesis enzymes and metallothionein. Proc Natl Acad Sci USA 88 23 (1991) 10591-10595
24. Moorehead R.A., and Singh G. Influence of the proto-oncogene c-fos on cisplatin sensitivity. Biochem Pharmacol 59 4 (2000) 337-345
25. Wilson L.A., Yamamoto H., and Singh G. Role of the transcription factor Ets-1 in cisplatin resistance. Mol Cancer Ther 3 7 (2004) 823-832
26. Eliopoulos A.G., et al. The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl-2. Oncogene 11 7 (1995) 1217-1228
27. Li J., et al. Human ovarian cancer and cisplatin resistance: possible role of inhibitor of apoptosis proteins. Endocrinology 142 1 (2001) 370-380
28. Fujie Y., et al. Oxaliplatin, a potent inhibitor of survivin, enhances paclitaxel-induced apoptosis and mitotic catastrophe in colon cancer cells. Jpn J Clin Oncol 35 8 (2005) 453-463
29. Huang R.Y., et al. Genome-wide screen identifies genes whose inactivation confer resistance to cisplatin in Saccharomyces cerevisiae. Cancer Res 65 13 (2005) 5890-5897
30. Fox M.E., Feldman B.J., and Chu G. A novel role for DNA photolyase: binding to DNA damaged by drugs is associated with enhanced cytotoxicity in Saccharomyces cerevisiae. Mol Cell Biol 14 12 (1994) 8071-8077
31. Ishida S., et al. Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc Natl Acad Sci USA 99 22 (2002) 14298-14302
32. Schenk P.W., et al. SKY1 is involved in cisplatin-induced cell kill in Saccharomyces cerevisiae, and inactivation of its human homologue, SRPK1, induces cisplatin resistance in a human ovarian carcinoma cell line. Cancer Res 61 19 (2001) 6982-6986
33. Schenk P.W., et al. Anticancer drug resistance induced by disruption of the Saccharomyces cerevisiae NPR2 gene: a novel component involved in cisplatin- and doxorubicin-provoked cell kill. Mol Pharmacol 64 2 (2003) 259-268
34. Qiu Y.Y., Mirkin B.L., and Dwivedi R.S. Inhibition of DNA methyltransferase reverses cisplatin induced drug resistance in murine neuroblastoma cells. Cancer Detect Prev 29 5 (2005) 456-463
35. Deng H.B., et al. Increased expression of dihydrodiol dehydrogenase induces resistance to cisplatin in human ovarian carcinoma cells. J Biol Chem 277 17 (2002) 15035-15043
36. Danford A.J., et al. Platinum anticancer drug damage enforces a particular rotational setting of DNA in nucleosomes. Proc Natl Acad Sci USA 102 35 (2005) 12311-12316
37. Kosmoski J.V., and Smerdon M.J. Synthesis and nucleosome structure of DNA containing a UV photoproduct at a specific site. Biochemistry 38 29 (1999) 9485-9494
38. Suquet C., and Smerdon M.J. UV damage to DNA strongly influences its rotational setting on the histone surface of reconstituted nucleosomes. J Biol Chem 268 32 (1993) 23755-23757
39. Zamble D.B., et al. Repair of cisplatin-DNA adducts by the mammalian excision nuclease. Biochemistry 35 31 (1996) 10004-10013
40. Moggs J.G., et al. Differential human nucleotide excision repair of paired and mispaired cisplatin-DNA adducts. Nucleic Acids Res 25 3 (1997) 480-491
41. Dabholkar M., et al. Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J Clin Invest 94 2 (1994) 703-708
42. Li Q., et al. Association between the level of ERCC-1 expression and the repair of cisplatin-induced DNA damage in human ovarian cancer cells. Anticancer Res 20 2A (2000) 645-652
43. Dabholkar M., et al. Increased mRNA levels of xeroderma pigmentosum complementation group B (XPB) and Cockayne's syndrome complementation group B (CSB) without increased mRNA levels of multidrug-resistance gene (MDR1) or metallothionein-II (MT-II) in platinum-resistant human ovarian cancer tissues. Biochem Pharmacol 60 11 (2000) 1611-1619
44. Metzger R., et al. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 16 1 (1998) 309-316
45. Koberle B., et al. Defective repair of cisplatin-induced DNA damage caused by reduced XPA protein in testicular germ cell tumours. Curr Biol 9 5 (1999) 273-276
46. Welsh C., et al. Reduced levels of XPA, ERCC1 and XPF DNA repair proteins in testis tumor cell lines. Int J Cancer 110 3 (2004) 352-361
47. Hector S., et al. In vitro studies on the mechanisms of oxaliplatin resistance. Cancer Chemother Pharmacol 48 5 (2001) 398-406
48. Reardon J.T., et al. Efficient nucleotide excision repair of cisplatin, oxaliplatin, and Bis-aceto-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) platinum intrastrand DNA diadducts. Cancer Res 59 16 (1999) 3968-3971
49. Hara R., Mo J., and Sancar A. DNA damage in the nucleosome core is refractory to repair by human excision nuclease. Mol Cell Biol 20 24 (2000) 9173-9181
50. Kosmoski J.V., Ackerman E.J., and Smerdon M.J. DNA repair of a single UV photoproduct in a designed nucleosome. Proc Natl Acad Sci USA 98 18 (2001) 10113-10118
51. Wang D., et al. Nucleotide excision repair from site-specifically platinum-modified nucleosomes. Biochemistry 42 22 (2003) 6747-6753
52. Hara R., and Sancar A. The SWI/SNF chromatin-remodeling factor stimulates repair by human excision nuclease in the mononucleosome core particle. Mol Cell Biol 22 19 (2002) 6779-6787
53. Fink D., et al. The role of DNA mismatch repair in platinum drug resistance. Cancer Res 56 21 (1996) 4881-4886
54. Karran P., Offman J., and Bignami M. Human mismatch repair, drug-induced DNA damage, and secondary cancer. Biochimie 85 11 (2003) 1149-1160
55. Obmolova G., et al. Crystal structures of mismatch repair protein MutS and its complex with a substrate DNA. Nature 407 6805 (2000) 703-710
56. Aebi S., et al. Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res 56 13 (1996) 3087-3090
57. Stojic L., Brun R., and Jiricny J. Mismatch repair and DNA damage signalling. DNA Repair (Amst) 3 8-9 (2004) 1091-1101
58. Durant S.T., et al. Dependence on RAD52 and RAD1 for anticancer drug resistance mediated by inactivation of mismatch repair genes. Curr Biol 9 1 (1999) 51-54
59. Drotschmann K., et al. Mutations in the nucleotide-binding domain of MutS homologs uncouple cell death from cell survival. DNA Repair (Amst) 3 7 (2004) 729-742
60. Clodfelter J.E.B.G.M., Gentry M.B., and Drotschmann K. MSH2 missense mutations alter cisplatin cytotoxicity and promote cisplatin-induced genome instability. Nucleic Acids Res 33 10 (2005) 3323-3330
61. Mesquita B., et al. No significant role for beta tubulin mutations and mismatch repair defects in ovarian cancer resistance to paclitaxel/cisplatin. BMC Cancer 5 (2005) 101
62. Aebi S., et al. Resistance to cytotoxic drugs in DNA mismatch repair-deficient cells. Clin Cancer Res 3 10 (1997) 1763-1767
63. Arzimanoglou I.I., et al. Microsatellite instability differences between familial and sporadic ovarian cancers. Carcinogenesis 17 9 (1996) 1799-1804
64. Cai K.Q., et al. Microsatellite instability and alteration of the expression of hMLH1 and hMSH2 in ovarian clear cell carcinoma. Hum Pathol 35 5 (2004) 552-559
65. Fujita M., et al. Microsatellite instability and alterations in the hMSH2 gene in human ovarian cancer. Int J Cancer 64 6 (1995) 361-366
66. Geisler J.P., et al. Mismatch repair gene expression defects contribute to microsatellite instability in ovarian carcinoma. Cancer 98 10 (2003) 2199-2206
67. Haas C.J., et al. Microsatellite analysis in serous tumors of the ovary. Int J Gynecol Pathol 18 2 (1999) 158-162
68. Orth K., et al. Genetic instability in human ovarian cancer cell lines. Proc Natl Acad Sci USA 91 20 (1994) 9495-9499
69. Pieretti M., et al. Genetic alterations distinguish different types of ovarian tumors. Int J Cancer 64 6 (1995) 434-440
70. Singer G., et al. Different types of microsatellite instability in ovarian carcinoma. Int J Cancer 112 4 (2004) 643-646
71. Nehme A., et al. Induction of JNK and c-Abl signalling by cisplatin and oxaliplatin in mismatch repair-proficient and -deficient cells. Br J Cancer 79 7-8 (1999) 1104-1110
72. Frankenberg-Schwager M., et al. Cisplatin-mediated DNA double-strand breaks in replicating but not in quiescent cells of the yeast Saccharomyces cerevisiae. Toxicology 212 2-3 (2005) 175-184
73. Adair G.M., et al. Role of ERCC1 in removal of long non-homologous tails during targeted homologous recombination. Embo J 19 20 (2000) 5552-5561
74. Ivanov E.L., and Haber J.E. RAD1 and RAD10, but not other excision repair genes, are required for double-strand break-induced recombination in Saccharomyces cerevisiae. Mol Cell Biol 15 4 (1995) 2245-2251
75. Sargent R.G., et al. Role of the nucleotide excision repair gene ERCC1 in formation of recombination-dependent rearrangements in mammalian cells. Nucleic Acids Res 28 19 (2000) 3771-3778
76. Sargent R.G., et al. Recombination-dependent deletion formation in mammalian cells deficient in the nucleotide excision repair gene ERCC1. Proc Natl Acad Sci USA 94 24 (1997) 13122-13127
77. De Silva I.U., et al. Defects in interstrand cross-link uncoupling do not account for the extreme sensitivity of ERCC1 and XPF cells to cisplatin. Nucleic Acids Res 30 17 (2002) 3848-3856
78. Groen H.J., et al. Carboplatin- and cisplatin-induced potentiation of moderate-dose radiation cytotoxicity in human lung cancer cell lines. Br J Cancer 72 6 (1995) 1406-1411
79. Havener J.M., et al. Translesion synthesis past platinum DNA adducts by human DNA polymerase mu. Biochemistry 42 6 (2003) 1777-1788
80. Hoffmann J.S., et al. DNA polymerase beta bypasses in vitro a single d(GpG)-cisplatin adduct placed on codon 13 of the HRAS gene. Proc Natl Acad Sci USA 92 12 (1995) 5356-5360
81. Masutani C., et al. Mechanisms of accurate translesion synthesis by human DNA polymerase eta. Embo J 19 12 (2000) 3100-3109
82. Vaisman A., and Chaney S.G. The efficiency and fidelity of translesion synthesis past cisplatin and oxaliplatin GpG adducts by human DNA polymerase beta. J Biol Chem 275 17 (2000) 13017-13025
83. Vaisman A., et al. Efficient translesion replication past oxaliplatin and cisplatin GpG adducts by human DNA polymerase eta. Biochemistry 39 16 (2000) 4575-4580
84. Albertella M.R., Lau A., and O'Connor M.J. The overexpression of specialized DNA polymerases in cancer. DNA Repair (Amst) 4 5 (2005) 583-593
85. Bergoglio V., et al. Enhanced expression and activity of DNA polymerase beta in human ovarian tumor cells: impact on sensitivity towards antitumor agents. Oncogene 20 43 (2001) 6181-6187
86. Canitrot Y., et al. Overexpression of DNA polymerase beta in cell results in a mutator phenotype and a decreased sensitivity to anticancer drugs. Proc Natl Acad Sci USA 95 21 (1998) 12586-12590
87. Horton J.K., et al. Strategic down-regulation of DNA polymerase beta by antisense RNA sensitizes mammalian cells to specific DNA damaging agents. Nucleic Acids Res 23 19 (1995) 3810-3815
88. Lin X., et al. DNA polymerase zeta accounts for the reduced cytotoxicity and enhanced mutagenicity of cisplatin in human colon carcinoma cells that have lost DNA mismatch repair. Clin Cancer Res 12 2 (2006) 563-568
89. Albertella M.R., et al. A role for polymerase eta in the cellular tolerance to cisplatin-induced damage. Cancer Res 65 21 (2005) 9799-9806
90. Hartmann J.T., and Lipp H.P. Toxicity of platinum compounds. Expert Opin Pharmacother 4 6 (2003) 889-901
91. Donzelli E., et al. Neurotoxicity of platinum compounds: comparison of the effects of cisplatin and oxaliplatin on the human neuroblastoma cell line SH-SY5Y. J Neurooncol 67 1-2 (2004) 65-73
92. Stachurska A., et al. Cisplatin up-regulates the in vivo biosynthesis and degradation of renal polyamines and c-Myc expression. Biochim Biophys Acta 1689 3 (2004) 259-266
93. Wagstaff A.J., et al. Carboplatin. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of cancer. Drugs 37 2 (1989) 162-190
94. Rybak L.P., and Whitworth C.A. Ototoxicity: therapeutic opportunities. Drug Discov Today 10 19 (2005) 1313-1321
95. Reddel R.R., et al. Ototoxicity in patients receiving cisplatin: importance of dose and method of drug administration. Cancer Treat Rep 66 1 (1982) 19-23
96. Lanvers-Kaminsky C., et al. Continuous or repeated prolonged cisplatin infusions in children: A prospective study on ototoxicity, platinum concentrations, and standard serum parameters. Pediatr Blood Cancer 47 2 (2006) 183-193
97. Banfi B., et al. NOX3, a superoxide-generating NADPH oxidase of the inner ear. J Biol Chem 279 44 (2004) 46065-46072
98. Lee J.E., et al. Role of reactive radicals in degeneration of the auditory system of mice following cisplatin treatment. Acta Otolaryngol 124 10 (2004) 1131-1135
99. Wang J., et al. Caspase inhibitors, but not c-Jun NH2-terminal kinase inhibitor treatment, prevent cisplatin-induced hearing loss. Cancer Res 64 24 (2004) 9217-9224
100. Kalkanis J.G., Whitworth C., and Rybak L.P. Vitamin E reduces cisplatin ototoxicity. Laryngoscope 114 3 (2004) 538-542
101. Fetoni A.R., et al. Protective effects of alpha-tocopherol and tiopronin against cisplatin-induced ototoxicity. Acta Otolaryngol 124 4 (2004) 421-426
102. Cassidy J., and Misset J.L. Oxaliplatin-related side effects: characteristics and management. Semin Oncol 29 5 Suppl 15 (2002) 11-20
103. Wolfgang G.H., et al. Comparative nephrotoxicity of a novel platinum compound, cisplatin, and carboplatin in male Wistar rats. Fundam Appl Toxicol 22 1 (1994) 73-79
104. Ikari A., et al. Sodium-dependent glucose transporter reduces peroxynitrite and cell injury caused by cisplatin in renal tubular epithelial cells. Biochim Biophys Acta 1717 2 (2005) 109-117
105. Lieberthal W., Triaca V., and Levine J. Mechanisms of death induced by cisplatin in proximal tubular epithelial cells: apoptosis vs. necrosis. Am J Physiol 270 4 Pt 2 (1996) F700-F708
106. Tanaka T., et al. Hypoxia-inducible factor modulates tubular cell survival in cisplatin nephrotoxicity. Am J Physiol Renal Physiol 289 5 (2005) F1123-F1133
107. Gorboulev V., et al. Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell Biol 16 7 (1997) 871-881
108. Ciarimboli G., et al. Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am J Pathol 167 6 (2005) 1477-1484
109. Yonezawa A., et al. Association between tubular toxicity of cisplatin and expression of organic cation transporter rOCT2 (Slc22a2) in the rat. Biochem Pharmacol 70 12 (2005) 1823-1831
110. Dickey D.T., et al. Protection against cisplatin-induced toxicities by N-acetylcysteine and sodium thiosulfate as assessed at the molecular, cellular, and in vivo levels. J Pharmacol Exp Ther 314 3 (2005) 1052-1058
111. Viale M., et al. Cisplatin combined with tiopronin or sodium thiosulfate: cytotoxicity in vitro and antitumor activity in vivo. Anticancer Drugs 10 4 (1999) 419-428
112. Meijer C., et al. Cisplatin-induced DNA-platination in experimental dorsal root ganglia neuronopathy. Neurotoxicology 20 6 (1999) 883-887
113. Pisano C., et al. Paclitaxel and Cisplatin-induced neurotoxicity: a protective role of acetyl-l-carnitine. Clin Cancer Res 9 15 (2003) 5756-5767
114. Bove L., et al. A pilot study on the relation between cisplatin neuropathy and vitamin E. J Exp Clin Cancer Res 20 2 (2001) 277-280
115. Halliwell B., and Gutteridge J.M.C. Free radicals in biology and medicine (1993), Oxford University Press, Oxford p. 188-276
116. Argyriou A.A., et al. A randomized controlled trial evaluating the efficacy and safety of vitamin E supplementation for protection against cisplatin-induced peripheral neuropathy: final results. Support Care Cancer (2006)
117. Orhan B., et al. Erythropoietin against cisplatin-induced peripheral neurotoxicity in rats. Med Oncol 21 2 (2004) 197-203
118. Bianchi R., et al. Protective effect of erythropoietin and its carbamylated derivative in experimental Cisplatin peripheral neurotoxicity. Clin Cancer Res 12 8 (2006) 2607-2612
119. Canetta R., Rozencweig M., and Carter S.K. Carboplatin: the clinical spectrum to date. Cancer Treat Rev 12 suppl A (1985) 125-136
120. Heinzlef O., Lotz J.P., and Roullet E. Severe neuropathy after high dose carboplatin in three patients receiving multidrug chemotherapy. J Neurol Neurosurg Psychiatry 64 5 (1998) 667-669
121. 2 over 3 h) employed in the treatment of gynecologic malignancies. J Cancer Res Clin Oncol 127 1 (2001) 55-58
122. Gamelin E., et al. Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures. Semin Oncol 29 5 Suppl 15 (2002) 21-33
123. Grolleau F., et al. A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels. J Neurophysiol 85 5 (2001) 2293-2297
124. Gamelin E., Gamelin L., and Delva R. Prevention of oxaliplatin peripheral sensory neuropathy by calcium + gluconate/Mg + chloride infusions: a retrospective study. Proc Am Soc Clin Oncol 21 (2002) a624
125. Grothey A. Clinical management of oxaliplatin-associated neurotoxicity. Clin Colorectal Cancer 5 Suppl 1 (2005) S38-S46
126. Tewari K.S., and Monk B.J. Gynecologic oncology group trials of chemotherapy for metastatic and recurrent cervical cancer. Curr Oncol Rep 7 6 (2005) 419-434
127. Jacobs C., et al. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 10 2 (1992) 257-263
128. Andrews P.A., et al. cis-Diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells. Cancer Res 48 1 (1988) 68-73
129. Dornish J.M., Melvik J.E., and Pettersen E.O. Reduced cellular uptake of cis-dichlorodiammine-platinum by benzaldehyde. Anticancer Res 6 4 (1986) 583-588
130. Dornish J.M., and Pettersen E.O. Protection from cis-dichlorodiammineplatinum-induced cell inactivation by aldehydes involves cell membrane amino groups. Cancer Lett 29 3 (1985) 235-243
131. Dornish J.M., and Pettersen E.O. Modulation of cis-dichlorodiammineplatinum(II)-induced cytotoxicity by benzaldehyde derivatives. Cancer Lett 46 1 (1989) 63-68
132. Pettersen E.O., et al. Antitumour effect of benzylidene-glucose (BG) in rats with chemically induced hepatocellular carcinoma. Anticancer Res 6 2 (1986) 147-152
133. Holzer A.K., et al. Cisplatin rapidly down-regulates its own influx transporter hCTR1 in cultured human ovarian carcinoma cells. Clin Cancer Res 10 19 (2004) 6744-6749
134. Song I.S., et al. Role of human copper transporter Ctr1 in the transport of platinum-based antitumor agents in cisplatin-sensitive and cisplatin-resistant cells. Mol Cancer Ther 3 12 (2004) 1543-1549
135. Holzer A.K., et al. The copper influx transporter human copper transport protein 1 regulates the uptake of cisplatin in human ovarian carcinoma cells. Mol Pharmacol 66 4 (2004) 817-823
136. Holzer A.K., Manorek G.H., and Howell S.B. The contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin and oxaliplatin. Mol Pharmacol (2006)
137. Komatsu M., et al. Copper-transporting P-type adenosine triphosphatase (ATP7B) is associated with cisplatin resistance. Cancer Res 60 5 (2000) 1312-1316
138. Nakayama K., et al. Expression and cisplatin sensitivity of copper-transporting P-type adenosine triphosphatase (ATP7B) in human solid carcinoma cell lines. Oncol Rep 8 6 (2001) 1285-1287
139. Nakayama K., et al. Copper-transporting P-type adenosine triphosphatase (ATP7B) as a cisplatin based chemoresistance marker in ovarian carcinoma: comparative analysis with expression of MDR1, MRP1, MRP2, LRP and BCRP. Int J Cancer 101 5 (2002) 488-495
140. Katano K., et al. Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of copper. Cancer Res 62 22 (2002) 6559-6565
141. Samimi G., et al. Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin, carboplatin, and oxaliplatin in ovarian cancer cells. Clin Cancer Res 10 14 (2004) 4661-4669
142. Samimi G., et al. Modulation of the cellular pharmacology of cisplatin and its analogs by the copper exporters ATP7A and ATP7B. Mol Pharmacol 66 1 (2004) 25-32
143. Ishikawa T., et al. Coordinated induction of MRP/GS-X pump and gamma-glutamylcysteine synthetase by heavy metals in human leukemia cells. J Biol Chem 271 25 (1996) 14981-14988
144. Lautier D., et al. Multidrug resistance mediated by the multidrug resistance protein (MRP) gene. Biochem Pharmacol 52 7 (1996) 967-977
145. Schrenk D., et al. Up-regulation of transporters of the MRP family by drugs and toxins. Toxicol Lett 120 1-3 (2001) 51-57
146. Liedert B., et al. Overexpression of cMOAT (MRP2/ABCC2) is associated with decreased formation of platinum-DNA adducts and decreased G2-arrest in melanoma cells resistant to cisplatin. J Invest Dermatol 121 1 (2003) 172-176
147. Shen D.W., et al. Decreased accumulation of [14C]carboplatin in human cisplatin-resistant cells results from reduced energy-dependent uptake. J Cell Physiol 183 1 (2000) 108-116
148. Safaei R., et al. Abnormal lysosomal trafficking and enhanced exosomal export of cisplatin in drug-resistant human ovarian carcinoma cells. Mol Cancer Ther 4 10 (2005) 1595-1604
149. Rudin C.M., et al. Inhibition of glutathione synthesis reverses Bcl-2-mediated cisplatin resistance. Cancer Res 63 2 (2003) 312-318
150. Godwin A.K., et al. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci USA 89 7 (1992) 3070-3074
151. Byun S.S., et al. Augmentation of cisplatin sensitivity in cisplatin-resistant human bladder cancer cells by modulating glutathione concentrations and glutathione-related enzyme activities. BJU Int 95 7 (2005) 1086-1090
152. Goto S., Kamada K., Soh Y., Ihara Y., and Kondo T. Significance of nuclear glutathione S-transferase pi in resistance to anti-cancer drugs. Jpn J Cancer Res 93 (2002) 1047-1056
153. Mayr D., Pannekamp U., Baretton G.B., Gropp M., Meier W., Flens M.J., et al. Immunohistochemical analysis of drug resistance-associated proteins in ovarian carcinomas. Pathol Res Pract 196 (2000) 469-475
154. Satoh T., Nishida M., Tsunoda H., and Kubo T. Expression of glutathione S-transferase pi (GST-pi) in human ovarian tumors. Eur J Obstet Gynecol Reprod Biol 96 (2001) 202-208
155. Surowiak P., Materna V., Kaplenko I., Spaczynski M., Dietel M., Lage H., et al. Augemented expression of metallothionein and glutathione S-transferase pi as unfavourable prognostic factors in cisplatin-treated ovarian cancer patients. Virchows Arch 447 (2005) 626-633
156. Nishimura T., Newkirk K., Session R.B., Andrews P.A., Trock B.J., Rasmussen A.A., et al. Immunohistochemical staining for glutathione S-transferase predicts response to platinum-based chemotherapy in head and neck cancer. Clin Cancer Res 2 (1996) 1859-1865
157. Ikeda K., Sakai K., Yamamotot R., Hareyama H., Tsumura N., Watari H., et al. Multivariate analysis for prognostic significance of histologica subtype, GST-pi, MDR-1, and p53 in stages II-IV ovarian cancer. Int J Gynecol Cancer 13 (2003) 776-786
158. Van der Zee A.G.J., Hollema H., Suurmeijer A.J.H., Krans M., Sluiter W.J., WIlemse P.H.B., et al. Value of P-glycoprotein, glutathione-S-transferase pi, c-erbB2, and p53 as prognostic factors in ovarian carcinomas. J Clin Oncol 13 (1995) 70-78
159. Konishi I., Nanbu K., Mandai M., Tsuruta Y., Kataoka N., and Nagata Y. Tumor response to neoadjuvant chemotherapy correlates with the expression of P-glycoprotein and PCNA but not GST-pi in the tumor cells of cervical carcinoma. Gynecol Oncol 70 (1998) 365-371
160. Miyatake K., Gemba K., Ueoka H., Mishii K., Kiura K., Tabata M., et al. Prognostic significance of mutant p53 protein, P-glycoprotein and glutathione S-transferase-pi in patients with unresectable non-small cell lung cancer. Anticancer Res 23 (2003) 2829-2836
161. Arner E.S.J., Nakamura H., Sasada T., Yodoi J., Homgren A., and Spyrou G. Analysis of the inhibition of mammalian thioredoxin, thioredoxin reductase; glutaredoxin by cis-diamminidischloroplatinum(II) and its major metabolite, the glutathione-platinum complex. Free Radic Biol Med 31 (2001) 1170-1178
162. Witte A.B., et al. Inhibition of thioredoxin reductase but not of glutathione reductase by the major classes of alkylating and platinum-containing anticancer compounds. Free Radic Biol Med 39 5 (2005) 696-703
163. Siegsmund M.J., Marx C., Seeman O., Schummer B., Steidler A., Toktomambetova L., et al. Cisplatin-resistant bladder carcinoma cells: enhanced expression of metallotioneins. Urol Res 27 (1999) 157-163
164. Toyoda H., Mizushima T., Satoh T., Izuka N., Nomoto A., Chiba H., et al. HeLa cell transformants overproducing mouse metallothionein show in vivo resistant to cis-platinum in nude mice. Jpn J Cancer Res 91 (2000) 91-98
165. Hishikawa Y., Koji T., Dhar D.K., Kinugasa S., Yamaguchi M., and Nagasue N. Metallothionein expression correlates with metastatic and proliferative potential in squamous cell carcinoma of the esophagus. Br J Cancer 81 (1999) 712-720
166. Siu L.L., Banerjee D., Khurana R.J., Pan X., Pflueger R., and Tannock I.F. The prognostic role of p53, metallothionein, P-glycoprotein, and MIB-1 in muscle-invasive urothelial transitional cell carcinoma. Clin Cancer Res 4 (1998) 559-564
167. Muramatsu Y., Yasegawa Y., Fukano H., Ogawa T., Namuba M., Mour S., et al. Metallothionein immunoreactivity in head and neck carcinomas - special reference to clinical behaviors and chemotherapy responses. Anticancer Res 20 (2000) 257-264
168. Meijer C., TImmer A., DeVries E.G., Groten J.P., Knol A., Zwart N., et al. Role of metallothionein in cisplatin sensitivity of germ-cell tumors. Int J Cancer 85 6 (2000) 777-781
169. Itamochi H., et al. Mechanisms of cisplatin resistance in clear cell carcinoma of the ovary. Oncology 62 4 (2002) 349-353